CD73 disruption with tumor-specific CRISPR/Cas9 nanoparticles reduces adenosine-mediated immunosuppression and amplifies response to chemotherapy
The therapeutic efficacy of cancer immunotherapy is impaired by poor tumor immunogenicity and the immunosuppressive tumor microenvironment (TME), partially driven by reprogrammed adenosine metabolism in the tumor. Here, we develop degradable CRISPR/Cas9 nanoparticles to durably and precisely downregulate CD73 expressio...